BioSpace News Archive

The Pulmonary Fibrosis Foundation (PFF) has launched the PFF Community Registry, a distinct data set of the PFF Registry™ that will collect participant-reported data provided directly by patients with pulmonary fibrosis (PF) and interstitial lung disease (ILD), their caregivers and family members, and lung transplant recipients previously diagnosed with PF or ILD.

BELLUS Health Inc. announced that it has completed its previously-announced underwritten public offering in Canada and the United States of 16,540,541 common shares at a price to the public of US$9.25 per common share.

Cells for Cells (“C4C”), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, announced a 6-month follow-up of the groundbreaking Clinical Data from the First-ever patient dosed with an exosome-produced therapy for osteoarthritis.

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced it will host a virtual R&D Day for analysts and investors at 9:00 am ET on Tuesday, July 26, 2022.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its second quarter 2022 financial results on Wednesday, August 3, 2022.

TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter of 2022 after market close on Monday, August 1, 2022.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced executive leadership and Board changes to help ensure the company realizes the full potential of its industry-leading genetics testing platform and delivers tangible and sustainable value for stockholders.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company’s board of directors, effective July 18,2022.

The Foundation for Angelman Syndrome Therapeutics (FAST) today announced that Ultragenyx Pharmaceutical Inc. has exercised its exclusive option to acquire GeneTx Biotherapeutics LLC, a biotechnology company founded and launched by FAST, and has closed on the acquisition.

Invitae (NYSE: NVTA), a leading medical genetics company, today announced a comprehensive plan to realize the full potential of its industry-leading genetics platform.